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Abstract  
BACKGROUND: Malignant melanoma is a disease which has a cutaneous origin in 90% of the patients, but in 
rare cases, it could be discovered as secondary deposits with unknown primary site. Metastatic Malignant 
Melanoma occurs without a primary site in about 3% of all melanoma patients, and it could be divided into two 
main groups: metastatic lymph nodes’ involvement or non-lymph nodes disease. The lack of unified classification 
and staging system, provided by AJCC (2009), as well as the lack for curtain diagnostic and therapeutic protocol, 
prompt us to raise the question what is the right way to precede in cases of metastasis of the lymph nodes, 
without evidence of a primary tumour?  
CASE REPORT: We report a case of 67-years- old woman who presented in the dermatology clinic after a 
surgical removal of an enlarged lymph node in her left femoral area, verified histologically as a metastasis of 
melanoma. After a diagnostic refinement in the clinic, the diagnosis of metastasis of malignant melanoma was 
confirmed by histology revision. We use the presented case to create for the first time in the world literature a 
novel stereotype of thinking, which is also followed by a stereotype of clinical behaviour – gentle to the patient, but 
providing a certain amount of security and satisfaction for the medical staff.  
CONCLUSION: The affection of a single lymph node in the absence of a primary tumour should not automatically 
lead to the conclusion that it is a single metastasis, but rather a primary melanoma of the lymph nodes, in cases 
of a negative PET scan, for example. In these cases, the measuring of the tumour thickness should guide the 
further therapeutic behaviour and determine the approach. 
 
 
 
 
 
 
 
 
Introduction 
 
Metastatic melanoma with unknown primary 
site (MUP) is defined as the progressive stage of 
disease, with no evidence of a primary tumour [1]. 
Although with rare incidence, metastatic melanoma 
with unknown primary site could occur in the lymph 
nodes, the skin or the inner organs, like lung, brain or 
liver metastasis, occupying 2-6% of all melanoma 
cases [1, 2]. According to results from a retrospective 
review for a period of ten years, made by 
Massachusetts General Hospital (MGH) and the 
Dana-Farber Cancer Institute (DFCI) the epidemiology 
of MUP shows higher prevalence of the cases, 
affecting the lymph nodes (35 patients), compared to 
those, affecting the skin (12 patients) or viscera (23 
patients) [2]. Although the aetiology of MUP is not fully 
understood, an unrecognised or misdiagnosed 
primary melanoma seems to be the most logical 
explanation for its occurrence [1, 3]. Regarding the 
fact that such primary lesion is usually not found, the 
strong immunological potential of melanoma itself, 
which could lead to incomplete or complete remission 
of the primary lesion by the host’s immune response 
has been implicated as a possible explanation of this 
phenomenon [3]. Another explanation for the possible 
reason for MUP is based on the theory that a prior 
lesion had been removed without a straight-laced 
histology or it is linked to nevus cell aggregates (NCA) 
in the lymph nodules [4, 5] It has been also 
hypothesized that ectopic melanocytes, located in 
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lymph nodes or inner organs could undergo malignant 
transformation in the same way as the cutaneous 
cells, in response to oncogenic stimuli or genetic 
predisposition [1, 6]. Hence, it has been established 
that relatives of patients with all kinds of cancers with 
unknown origin are at increased risk of developing the 
same, or other malignancies, including lung, 
pancreatic and colon cancers [6]. This in term 
confirms the pleomorphic nature and oncogenesis of 
these types of cancers, which remain in top 5 reasons 
for dead among cancer’s patient around the world [1]. 
Most of the cases have been diagnosed at stage III, 
followed by stage IV disease, while the most common 
primary site of metastatic affection is the lymph nodes, 
followed by lungs and skin [1]. Staging classification 
resembles this in cutaneous melanoma, where limited 
cutaneous or nodal metastasis are classified in stage 
III, in contrast to those, disseminated in various body 
sites – in stage IV [1, 2]. 
Although, there is no significant differentiation 
in staging between MUP and melanoma with known 
origin, according to American Join Committee of 
Cancers’ recommendations from 2009, there are 
some differences in the biological behaviour, as well 
as in the prognostic rate and genetic signature of 
these two sides of the same coin [1]. MUP patients 
have a better prognosis than those with metastatic 
melanoma with a known primary and better survival 
rate compared to non-lymph nodes MUP in general [1, 
3]. Herein, we present a case of metastatic melanoma 
in the lymph node, without evidence of primary site 
tumour, as we focus the attention on some critical 
points in the diagnostic and therapeutic behaviour, 
which are often challenging.  
 
 
Case report 
 
We present a 67-years-old Caucasian female 
patient who came to the dermatology clinic for a 
diagnostic clarification and follow up. A surgical 
removal of an atypical and enlarged lymph node in the 
left femoral area was done a month ago, according to 
her medical history (Fig. 1a). Detailed medical history 
was obtained, but the patient did not report any 
precipitating event for the swelling. Postoperatively, 
the histological evaluation confirmed: metastases in 
the lymph node from Melanoma (Fig. 1b, c, d). 
Comorbidities include colon irritable, stomach polyps, 
arterial hypertension, endometrial hyperplasia, uterine 
fibroids. No surgical history was reported before the 
lymph node removal. The patient was recommended 
for a diagnostic refinement which was done in a 
month after the surgical treatment in an internal 
disease clinic. All necessary examinations for 
confirmation of the diagnosis of MUP according to the 
oncology protocols [7] were done. The patient 
underwent thorough examinations, including detailed 
medical history, physical examinations and 
consultations with different medical specialists, as well 
as positron emission tomography (PET scan), 
biochemical and haematological tests and histology 
revision. Physical examination with 
otorhinolaryngology specialist showed up two 
enlarged lymph nodes in her neck: one at each side: 
measuring 2/1 cm, painless, firm on palpation and 
non-fluctuant. The overlying skin was described as 
intact with no redness. 
Figure 1: a) Patient with melanoma of the lymph node, treated 
surgically; b, c, d) Tumour cells infiltrating the lymphatic node 
 
PET scan performed with oral and i.v. 
contrast did not show any abnormalities. No primary 
site tumour evidence or metastatic lesion was seen. 
Physical examination with gastroenterologist, 
gynecologist and ophthalmologists were done. The 
genital examination did not detect any primary site 
lesion. Both gastroscopies of gullet, stomach and 
duodenum and colonoscopy did not reveal any 
abnormalities which could be related to a primary site 
tumour. Blood tests established high levels of S-
protein and LDH, considered as markers for 
melanoma. Second histology revision confirmed 
metastases of malignant melanoma as the previous 
one. The patient was referred for 
immunohistochemical tests, which revealed a positive 
staining for Melan A and HMB 45.  
 
 
Discussion 
 
Metastatic melanoma of unknown origin is a 
diagnosis of exclusion. A wide range of diagnostic 
procedures should be performed to exclude primary 
cutaneous, lymph node or visceral organ affection [1, 
2]. Except for the ordinary diagnostic procedure with 
clinical examination, blood tests, biochemistry and 
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imaging diagnosis in order to exclude metastatic 
spread in melanoma with cutaneous or mucosal 
origin, a multidisciplinary approach is required to 
exclude any primary involvement in cases of 
metastatic disease, including otorhinolaryngological 
examination; ophthalmological examination, 
gynecological examination for women and urological 
for men [8]. Although imaging diagnostic procedures 
are also considered helpful, some studies show that 
although better than CT scan in lymph node staging, 
the false-positive rate is high in PET-positive lymph 
nodes measuring less than 1 cm in diameter [9]. 
Although F-18 FDG PET/CT is found as a useful 
method in staging cutaneous and non-cutaneous 
melanoma, an extremely low detection rate is reported 
in locating the primary carcinoma of metastatic 
melanoma and axillary metastasis in patients with 
cancer of unknown primary site [10]. Differentiation in 
genetic signature of primary and metastatic melanoma 
with unknown origin has also been provided, with a 
higher rate of mutations in BRAF and NRAS genes in 
MUP patients, as well as more common mutations in 
TERT-promoter [1]. Although promising, these 
discoveries could not be implicated as routine 
diagnostic procedures, because of the high price of 
the method and its limitations.  
The lack of unified classification and staging 
system, provided by AJCC (2009), as well as the lack 
for certain diagnostic and therapeutic protocol, prompt 
us to raise the question what is the right way to 
proceed in cases of metastasis of the lymph nodes, 
without evidence of a primary tumour? Furthermore, 
the lack of unified including criteria and staging in all 
of the studies on that issue often leads to 
contradictory results regarding the best diagnostic 
approach and prognosis rate, which additionally 
confuse the clinicians and patients themselves.  
We use the presented case to create for the 
first time in the world literature a stereotype of 
thinking, which is also followed by a stereotype of 
clinical behaviour – gentle to the patient but providing 
a certain amount of security and satisfaction for the 
medical staff. The important point is to pay accurate 
attention to these data in future guidelines, which are 
not insignificant.  
The affection of a single lymph node in the 
absence of a primary tumour should not automatically 
lead to the conclusion that it is a single metastasis, 
but rather a primary melanoma of the lymph nodes, in 
cases of a negative PET scan, for example. In these 
cases, the measuring of the tumour thickness should 
guide the further therapeutic behaviour and determine 
the approach. Herein, we suggest the staging of MUP 
to be similar to stage I and II of cutaneous melanoma 
but strictly referred to the primary melanoma of the 
lymph nodes. 
In this way, a lymphadenectomy should be 
recommended for tumours with thickness over 1 mm, 
or less than 1 mm, but with additional risk factors such 
as increased number of mitosis, age under 40 years, 
vessels invasion, and so on. This group should also 
include cases of melanomas that have been 
regressed and subsequent they could not be detected 
after the metastatic spread. But we should not forget 
that the mucosal melanomas can be amelanotic and 
composed by up to a hundred malignant cells, which 
would be undetectable on PET scan also. 
Despite all the mentioned variants, the 
presence of several affected lymph nodes should be 
interpreted as a sure marker for metastatic disease, 
weather, the affection of a single lymph node is more 
indicative for a primary lymph node melanoma, which 
would require more soft approach in cases with 
smaller tumour thickness, or at least in some 
acceptable limits with which clinicians should comply 
with. Therefore, the former statement that MUP of 
single lymph nodes has similarities to Stage III 
disease and should be treated with aggressive 
surgical management [11] is no longer needed.  
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